Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

Brózik A, Hegedüs C, Erdei Z, Hegedus T, Özvegy-Laczka C, Szakács G, Sarkadi B.

Expert Opin Drug Metab Toxicol. 2011 May;7(5):623-42. doi: 10.1517/17425255.2011.562892. Epub 2011 Mar 17. Review.

PMID:
21410427
2.

ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.

Deng J, Shao J, Markowitz JS, An G.

Pharm Res. 2014 Sep;31(9):2237-55. doi: 10.1007/s11095-014-1389-0. Epub 2014 May 20. Review.

PMID:
24842659
3.

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.

Hegedus C, Ozvegy-Laczka C, Apáti A, Magócsi M, Német K, Orfi L, Kéri G, Katona M, Takáts Z, Váradi A, Szakács G, Sarkadi B.

Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28.

4.

Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.

Beretta GL, Cassinelli G, Pennati M, Zuco V, Gatti L.

Eur J Med Chem. 2017 Dec 15;142:271-289. doi: 10.1016/j.ejmech.2017.07.062. Epub 2017 Aug 3. Review.

PMID:
28851502
5.

Reversing multidrug resistance by tyrosine kinase inhibitors.

He M, Wei MJ.

Chin J Cancer. 2012 Mar;31(3):126-33. doi: 10.5732/cjc.011.10315. Epub 2012 Jan 9. Review.

6.

TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.

D'Cunha R, Bae S, Murry DJ, An G.

Biopharm Drug Dispos. 2016 Oct;37(7):397-408. doi: 10.1002/bdd.2022. Epub 2016 Sep 13.

PMID:
27418107
7.

Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins.

Wang XK, Fu LW.

Curr Drug Metab. 2010 Sep;11(7):618-28. Review.

PMID:
20812904
8.

Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.

Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B.

Drug Resist Updat. 2005 Feb-Apr;8(1-2):15-26. Review.

PMID:
15939339
9.

Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.

Azzariti A, Porcelli L, Simone GM, Quatrale AE, Colabufo NA, Berardi F, Perrone R, Zucchetti M, D'Incalci M, Xu JM, Paradiso A.

Cancer Chemother Pharmacol. 2010 Jan;65(2):335-46. doi: 10.1007/s00280-009-1039-0.

PMID:
19495754
10.

Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.

Hartmann JT, Haap M, Kopp HG, Lipp HP.

Curr Drug Metab. 2009 Jun;10(5):470-81. Review.

PMID:
19689244
11.

Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.

Erdem L, Giovannetti E, Leon LG, Honeywell R, Peters GJ.

Curr Top Med Chem. 2012;12(15):1649-59. Review.

PMID:
22978339
12.

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.

Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE.

Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27.

13.
14.

Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors.

Shao J, Markowitz JS, Bei D, An G.

J Pharm Sci. 2014 Dec;103(12):3810-3833. doi: 10.1002/jps.24113. Epub 2014 Oct 10. Review.

PMID:
25308414
15.

Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction.

Fleisher B, Unum J, Shao J, An G.

J Pharm Sci. 2015 Jan;104(1):266-75. doi: 10.1002/jps.24289. Epub 2014 Nov 21.

PMID:
25418056
16.

Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters.

Da Silva CG, Honeywell RJ, Dekker H, Peters GJ.

Expert Opin Drug Metab Toxicol. 2015 May;11(5):703-17. doi: 10.1517/17425255.2015.1006626. Epub 2015 Jan 29. Review.

PMID:
25633410
17.

Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.

Shukla S, Robey RW, Bates SE, Ambudkar SV.

Drug Metab Dispos. 2009 Feb;37(2):359-65. doi: 10.1124/dmd.108.024612. Epub 2008 Oct 29.

18.

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.

Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, Ambudkar SV, Chen ZS.

Cancer Res. 2007 Nov 15;67(22):11012-20.

19.

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.

Lemos C, Jansen G, Peters GJ.

Br J Cancer. 2008 Mar 11;98(5):857-62. doi: 10.1038/sj.bjc.6604213. Epub 2008 Feb 5. Review.

20.

Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.

Anreddy N, Gupta P, Kathawala RJ, Patel A, Wurpel JN, Chen ZS.

Molecules. 2014 Sep 4;19(9):13848-77. doi: 10.3390/molecules190913848. Review.

Supplemental Content

Support Center